Biological Psychology: Body Rhythms and Seasonal Affective Disorder (SAD)

Overview of Seasonal Affective Disorder (SAD)

Definition of SAD: Seasonal Affective Disorder is classified as a mood disorder characterized by episodes of major depression occurring specifically during the autumn and winter months.
Core Symptoms: Individuals suffering from SAD experience a range of symptoms including: * Low mood and feelings of hopelessness. * Increased tiredness and a tendency toward oversleeping. * A distinct lack of motivation and withdrawal from activities previously found interesting. * Significant changes in appetite.
Impact on Daily Life: These symptoms collectively impact the individual’s daily activities and overall quality of life.
General Theory of Causality: SAD is primarily thought to be caused by reduced exposure to daily natural light due to shorter day lengths in winter, which disrupts the biological circadian sleep-wake cycle.

Theoretical Causes and Biological Mechanisms

Circadian Rhythm Disruption: Shortened daylight hours impact the body's internal clock. Alfred Lewy et al. (2007) suggested that SAD occurs because the circadian rhythm is typically "phase delayed."
The Role of Melatonin: Fluctuations in melatonin production in response to increased darkness may account for the symptoms of excessive tiredness and oversleeping seen in SAD patients.
The Role of Serotonin: * Light exposure is known to regulate neurotransmitters, particularly serotonin. * Serotonin is responsible for regulating mood and promoting feelings of well-being. * Low light levels reduce serotonin activity, which subsequently results in low mood.
Serotonin Reuptake Theory: One prevailing theory suggests that individuals with SAD experience an increase in the reuptake of serotonin. This leaves less serotonin in the synaptic gap, triggering depressive symptoms.

Key Research into SAD Prevalence and Behaviors

Correlation with Latitude: Erin Michalak and Raymond Lam (2002) reviewed $22$ studies and found a correlation of $0.66$ between latitude and the prevalence of SAD. This confirms that shorter days in the north are associated with higher rates of the disorder.
Migration and Genetic Sensitivity: * Andrés Magnusson and Jóhann Axelsson (1993) investigated Icelanders who migrated south to Manitoba, Canada. * They compared them to locals at the same latitude and found lower rates of SAD among the migrated Icelanders. This suggests Icelanders may have a lower genetic sensitivity to the disorder.
Social Media Analysis (Mood and Seasonality): * Scott Golder and Michael Macy (2011) analyzed $509 \times 10^6$ Twitter (X) messages across $84$ countries. They found a direct relationship between decreased day length and a reduction in positive emotions expressed online. * Fabon Dzogang et al. (2017) analyzed $800 \times 10^6$ social media messages and the purchase of health products. They found that sadness in messages and the purchase of fatigue/tiredness remedies were significantly higher during winter months.
Seasonal Fluctuations in Caloric Intake and Appetite: * Yunsheng Ma et al. (2006) conducted a longitudinal study of $593$ participants in Massachusetts, USA. They found average calorie consumption was $86\,kcal$ per day higher in the autumn than in the spring. * Samuel Serisier et al. (2014) performed a four-year study on animal subjects (cats) and found they consumed average of $15\%$ more food in winter months ( $\text{October to February}$ ) compared to summer months ( $\text{June to August}$ ).
Melatonin Levels in SAD Patients: Konstantin Danilenko et al. (1994) found high levels of melatonin during the daytime of winter months in SAD patients compared to healthy controls. These differences disappeared after light treatment or during the summer. However, other research has failed to consistently replicate these findings regarding melatonin differences between SAD patients and controls.

Therapies for Seasonal Affective Disorder: Light Therapy

Phototherapy Mechanism: Light therapy involves exposing the patient to a very bright light source, often a "light box."
Purpose: It is used during winter to compensate for reduced natural daylight. It is thought to reduce melatonin production and increase serotonin availability while correcting the winter circadian phase delay.
Standard Regimen: * Exposure to light of approximately $10,000\,lux$ . * Duration of $20\text{--}60\,minutes$ daily during autumn and winter. * Timing: Usually performed in the morning just after waking to reset the internal body clock and regulate the sleep-wake cycle.
Clinical Efficacy Studies: * Norman Rosenthal et al. (1984): One of the first trials where SAD patients were exposed to bright light in the morning and evening for $2\,weeks$ . Results showed a significant reduction in depression ratings. Conversely, dim light exposure increased depression ratings, proving effectiveness depends on luminosity. * Robert Golden et al. (2005): A meta-analysis of randomized controlled trials. They found bright light treatment significantly reduced the severity of depressive symptoms in various mood disorders. Specifically, dawn light exposure was effective for SAD at a rate equivalent to standard antidepressant medication trials. * Charmaine Eastman et al. (1998): Studied $96$ SAD patients across three groups: morning bright white light ( $1.5\,hours$ for $4\,weeks$ ), evening white light, and a morning placebo (sham negative-ion generators with red and green light). After $3\,weeks$ , the morning bright light group showed greater symptom reduction than the placebo group.

Evaluation of Light Therapy

Strengths: * Considered a non-invasive therapy. * Can be a safer alternative to medication for many people.
Side Effects and Limitations: * Side effects include headaches, nausea, and eyestrain. * Not recommended for individuals with glaucoma, cataracts, or those taking photosensitive medication (e.g., certain antibiotics). * Heavy time commitment: Patients may need to sit in front of the box for extended periods each morning, which can interfere with daily routines.

Antidepressants as a Biological Treatment

Standard Recommendations: The National Institute for Health and Care Excellence (NICE) recommends treating SAD the same way as other mood disorders, using talking therapies (like CBT) or antidepressants.
SSRIs (Selective Serotonin Reuptake Inhibitors): These are the most common medications for SAD. They work by blocking the reuptake of serotonin by binding to transporters, leaving more serotonin in the synaptic gap to elevate mood.
Clinical Research for Antidepressants: * Raymond Lam et al. (1995): Compared fluoxetine (an SSRI) with a placebo in $68$ patients with winter depression. $59\%$ of the fluoxetine group showed a $50\%$ or greater reduction in symptoms compared to $39\%$ in the placebo group after $5\,weeks$ . * Adam Moscovitch et al. (2004): Studied $187$ SAD patients using sertraline in flexible doses ( $50\,mg$ to $200\,mg$ per day) for $8\,weeks$ . It was significantly more effective than a placebo. Patient drop-out rates were very low in this study. * Serotonin Agonists: Robert Levitan et al. (1998) used a double-blind, randomized placebo trial on $14$ female patients. Those taking serotonin agonists reported significantly less sadness and subjective euphoria.

Comparative Evaluation: Light Therapy vs. Antidepressants

Raymond Lam et al. (2006): Randomly assigned SAD patients to either fluoxetine plus placebo light (dim light) or light therapy plus a placebo pill. * Medication Dose: Fluoxetine was fixed at $50\,mg$ per day. * Duration: $8\,weeks$ . * Findings: No significant difference was found in overall effectiveness; both were equally effective at reducing symptoms.
Differentiating Factors: * Speed of Action: Light therapy was quicker to take effect compared to antidepressant medication. * Side Effects: Medication can cause headaches, nausea, and rarely, serotonin syndrome. They often take weeks to show results. * Burden: Medication is a daily pill burden, while light therapy is a daily time-commitment burden.

General Evaluation and Ethical Considerations

Placebo Effect Issues: In many studies, it is difficult to determine if improvements are biological or due to the placebo effect (the expectation of improvement), as participants usually know whether they are receiving light therapy.
Ethical Concerns in Research: Placebo trials for SAD involve withholding proven effective therapy from a control group, which is ethically problematic if symptoms are severe.
Individual Variation: There is high individual variation in symptom severity and response to treatment, which may be influenced by specific differences in individuals' circadian rhythms.
Research Gaps: There is a need for long-term research to see if these therapies reduce the recurrence of SAD in the future. The exact biological mechanisms through which light therapy alters neurotransmitters are not yet fully understood.

Key Terminology

Agonist: A chemical substance (drug) that binds to and activates a receptor to cause a signal, mimicking a neurotransmitter.
Double-blind: A study design where neither the participants nor the researchers collecting data know who is receiving the active treatment.
Placebo: An inactive substance that has no actual biological impact but may be perceived by the user as having an effect.
Placebo Effect: Improvement in symptoms shown because of the participant's expectation that improvement will occur.

Questions & Discussion

CHECKPOINT

Which of the statements are true and which are false? * Prompt fragment: "The nineal [pineal] gland secretes melatonin in…" * Note: The transcript segment for this checkpoint is incomplete in the source material provided.